How can CE or FDA evidence support an Australian TGA application?

Author:Sonictec · 2026-10-21 Updated

Overseas authorisation does not complete Australian market access

CE marking or FDA authorisation can provide an important foundation for an Australian application, but ordinarily does not itself permit commercial supply in Australia. Unless an exemption, exclusion or special access arrangement applies, a medical device needs inclusion in the Australian Register of Therapeutic Goods (ARTG), with an Australian sponsor responsible for the relevant application and ongoing obligations. Overseas authorisation can support the evidence; it does not create an Australian entry.

Start with four questions: what exactly will be supplied, how is it classified in Australia, do the overseas documents cover it, and who will be responsible for Australian supply? This guide follows those questions, using official sources checked on 21 October 2026. Required document combinations and review requirements vary with device class and certificate status.

Source:TGA: steps to supply medical devices for Sponsors ；TGA: Evidence requirements for medical device market authorisation

Apply Australian classification rules before selecting evidence

General medical devices are classified as MD Class I, IIa, IIb or III, with additional distinctions such as sterility and measuring function within Class I. IVDs use Classes 1 to 4; IIa and IIb should not be applied to diagnostic reagents. Classification depends on intended purpose, the site and duration of contact, implantation, active operation, users and use settings, as relevant.

The same device can have different EU and Australian classifications. An overseas classification is useful context, but the Australian application needs its own rationale. Ordinary non-sterile, non-measuring Class I devices have different evidence requirements from high-risk devices, so absence of CE marking does not invariably mean a full TGA conformity assessment is required.

Source:TGA: Evidence requirements for medical device market authorisation

What CE, FDA and MDSAP evidence can support

TGA accepts documents from comparable overseas regulators and assessment bodies under specified conditions. Check the current guidance for applicable device classes and document combinations covering EU notified bodies, US FDA authorisations and relevant Canadian, Japanese, Singaporean and UK evidence. The May 2026 update added UK Approved Bodies. The issuing country or certificate cover alone does not establish acceptability.

MDSAP principally supplies quality management system audit evidence, not product market authorisation. Whether product-level authorisation is also required depends on Australian classification and the specific route. TGA has particular guidance on MDSAP for Class 2 and Class 3 IVDs, so neither “every device needs MDSAP plus 510(k)” nor “MDSAP alone permits supply” is a reliable rule.

Source:TGA: Using comparable overseas regulatory evidence ；TGA: MDSAP frequently asked questions

How manufacturer evidence connects to an ARTG application

For a device requiring manufacturer evidence, the sponsor submits the applicable Manufacturer Evidence (ME) through TGA Business Services and obtains an accepted evidence record before referencing it in the corresponding ARTG application. Check manufacturer identity, certificates and device scope; uploading a certificate scan is not completion of device registration.

There are two different processes: using accepted overseas documents to support ARTG inclusion, and using overseas assessment results to support abridgement when seeking a TGA-issued conformity assessment certificate. The latter is commonly called abridged assessment. Not every ARTG application using CE or FDA documents follows one uniform “simplified registration” procedure.

An ARTG application may still be selected for application audit, with technical or clinical documentation and responses to further questions required. Have retrievable documents ready before submission and respond within the specified deadlines. Application audit and manufacturing-site audit are different activities and should not be conflated when estimating work or fees.

Source:TGA: Manufacturer evidence ；TGA: Using comparable overseas regulatory evidence ；TGA: application audits and information requests

Map certificates to the actual Australian product range

Prepare a device-to-evidence matrix listing the manufacturer, intended purpose, user, key specifications, Australian class and supporting certificate annexes for each model. If a certificate covers models A, B and C but only B is proposed for Australia, identify that subset clearly. If it supports a standard version but an enhanced version is proposed, establish whether the additional version is covered rather than grouping them by similar names.

Legacy EU certificates require checks of transition conditions, validity extensions and Australian acceptance arrangements. The printed expiry date alone may not establish current status, and an MDR application does not automatically keep a legacy certificate valid. Review the certificate, notified-body confirmation, transition eligibility and proposed submission timing together.

Source:TGA: Using comparable overseas regulatory evidence ；TGA: Manufacturer evidence

Australian labelling, clinical evidence and Essential Principles still apply

Review medical device labelling against the Australian Essential Principles, particularly Principle 13, and the sponsor-information rules. Check English information, manufacturer details, lot or serial identifiers, instructions, warnings and applicable arrangements for the sponsor’s name and address. An ARTG number is not a universal mandatory item on every medical device label; assess UDI, implant cards and device-specific rules separately.

Clinical material prepared for the EU or US can provide a basis for review, but it must relate to the relevant device, intended use and population and support the Australian safety and performance claims. An existing clinical evaluation report still requires review. Australian entry does not automatically require a new local trial; additional evidence depends on the identified gaps and applicable requirements.

An EU GSPR checklist can help organise the material, but an Australian EP checklist should identify applicability, standards and the location of supporting evidence for each principle. Changing the heading is not enough. Align the manufacturer’s declaration, risk management, verification and clinical evaluation with the claims in the instructions for use.

Source:TGA: Medical device labelling requirements ；TGA: Essential Principles compliance ；TGA: Evidence requirements for medical device market authorisation

Plan timelines and costs by the work actually required

Separate document preparation, applicable ME processing, the ARTG application and any audit, and pre-supply labelling and channel preparation. Classification, completeness, audit selection and response times affect the schedule. CE marking alone does not justify a fixed approval promise, and an official processing target is not a guaranteed end-to-end commercial launch date.

Budget separately for application fees, applicable audit or conformity assessment fees, ongoing annual charges, sponsor services and technical preparation. Official charges change by financial year, so this article does not reuse old amounts. Consult the current TGA schedule below and specify device class, application count, additional-response work and post-market maintenance in the quotation.

Source:TGA: current application fees and annual charges ；TGA: application audits and information requests

Documents to prepare for an initial assessment

You do not need to translate the entire technical file before an initial assessment. Start with the materials below to assess Australian classification, usable evidence and gaps, then arrange fuller technical review once the scope is agreed. Sonictec can use this information to discuss the TGA registration and sponsor engagement.

• Device list, models, intended purpose, users, marketed versions and proposed Australian customers.
• Complete overseas certificates and annexes, FDA decision documents, QMS documents and evidence of any legacy transition or renewal.
• Current labels, instructions, clinical evaluation summary, index of key verification reports and declaration of conformity.
• Existing ARTG and sponsor arrangements, target timing and any unresolved model or intended-use changes.

Source:TGA: Evidence requirements for medical device market authorisation

Further reading

• What should be checked for TGA when CE or FDA documentation already exists?
• What should you prepare before a TGA registration consultation?
• What is included in a TGA quote? Comparing service fees, official fees and annual charges